RT Journal Article
SR Electronic
T1 Disease progression and clinical outcomes in latent osteoarthritis phenotypes: Data from the Osteoarthritis Initiative
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.14.23299525
DO 10.1101/2023.12.14.23299525
A1 Huang, Zeyu
A1 Bucklin, Mary A.
A1 Guo, Weihua
A1 Martin, John T.
YR 2023
UL http://medrxiv.org/content/early/2023/12/15/2023.12.14.23299525.abstract
AB The prevalence of knee osteoarthritis (OA) is widespread and the heterogeneous patient factors and clinical symptoms in OA patients impede developing personalized treatments for OA patients. In this study, we used unsupervised and supervised machine learning to organize the heterogeneity in knee OA patients and predict disease progression in individuals from the Osteoarthritis Initiative (OAI) dataset. We identified four distinct knee OA phenotypes using unsupervised learning that were defined by nutrition, disability, stiffness, and pain (knee and back) and were strongly related to disease fate. Interestingly, the absence of supplemental vitamins from an individual’s diet was protective from disease progression. Moreover, we established a phenotyping tool and prognostic model from 5 variables (WOMAC disability score of the right knee, WOMAC total score of the right knee, WOMAC total score of the left knee, supplemental vitamins and minerals frequency, and antioxidant combination multivitamins frequency) that can be utilized in clinical practice to determine the risk of knee OA progression in individual patients. We also developed a prognostic model to estimate the risk for total knee replacement and provide suggestions for modifiable variables to improve long-term knee health. This combination of unsupervised and supervised data-driven tools provides a framework to identify knee OA phenotype in a clinical scenario and personalize treatment strategies.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/weihuaguo/cluster_oai. Funding StatementDr. Zeyu Huang wishes to acknowledge funding from the National Natural Science Foundation of China (NSFC: 92049101; 81972097; 81702185) and Sichuan Science and Technology Programs (No. 2022YFH0101, 2018HH0071). Dr. John T. Martin wishes to acknowledge funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K99 AR077685, R00 AR077685).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study utilizes publicly available de-identified human data from the Osteoarthritis Initiative.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript